EVALUATION OF THERAPIES FOR PNEUMOCYSTIS CARINI

卡里尼肺孢子虫治疗的评估

• 批准号: 2295457
• 负责人: PETER WAIZER
• 金额: $ 55.7万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-07-10 至 1997-07-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2295457
• 关键词: EVALUATION; THERAPIES; PNEUMOCYSTIS; CARINI; EVALUATION; THERAPIES; PNEUMOCYSTIS; CARINI

Current therapies to treat opportunistic infections associated with the Acquired Immunodeficiency Syndrome (AIDS) are highly toxic, extremely expensive or marginally effective. Because present therapies for certain infections produce toxic reactions in a large percentage of patients, the availability of alternative therapeutics are of utmost importance. Since these infections produce significant morbidity and mortality in patients with AIDS, the National Institute of Allergy and Infectious Diseases (NIAID) has funded several programs to facilitate drug development efforts against opportunistic infections by providing contract resources for efficacy evaluations in animals, a critical component in new drug approval. The availability of animal model testing systems will provide the NIAID with testing capabilities to evaluate therapies for treatment against Pneumocystis carinii, both singly and in combination as well as determine the pharmacokinetics and toxicities of the experimental therapies. This will permit the submission of the resulting data in support of an IND application for the new therapy. The contractor will have the capability to evaluate therapeutic agents in small animal (in vivo) and culture (in vitro) model test systems, develop alternative protocols to accommodate special characteristics of individual therapies of model test systems, measure general toxicity, determine pharmacokinetic parameters, etc, to assist the sponsor in the development of new therapies against P. carinii.

当前治疗与机会感染的疗法 获得的免疫缺陷综合征（AIDS）是有毒的，极度毒性 昂贵或略有效率。 因为目前的疗法 某些感染产生有毒反应 患者，替代疗法的可用性是最大的 重要性。 由于这些感染会产生明显的发病率和 艾滋病患者的死亡率，国家过敏研究所 传染病（NIAID）已资助了几项计划，以促进 通过提供的药物开发努力，以防止机会性感染 合同资源用于动物的功效评估，这是关键的 新药批准的组成部分。 动物模型的可用性 测试系统将为NIAID提供测试功能 评估针对肺炎胸藻的治疗疗法，都 单独，结合在一起，并确定药代动力学和 实验疗法的毒性。 这将允许 提交结果数据以支持IND应用程序 新疗法。 承包商将有能力评估 小动物（体内）和培养物（体外）的治疗剂 模型测试系统，开发替代协议以适应特殊 模型测试系统各个疗法的特征，测量 一般毒性，确定药代动力学参数等以帮助 针对Carinii的新疗法开发的赞助商。